Latest Rhenman & Partners Asset Management AB Stock Portfolio

Rhenman & Partners Asset Management AB Performance:

2025 Q4: 10.83%YTD: 14.42%2024: 4.61%

Performance for 2025 Q4 is 10.83%, and YTD is 14.42%, and 2024 is 4.61%.

About Rhenman & Partners Asset Management AB and 13F Hedge Fund Stock Holdings

On 2026-02-13, the fund reported it's updated stock portfolio. In the 13F Holdings report, Rhenman & Partners Asset Management AB reported an equity portfolio of $1.1 Billions as of 31 Dec, 2025.

The top stock holdings of Rhenman & Partners Asset Management AB are REGN, LLY, BSX. The fund has invested 4.4% of it's portfolio in REGENERON PHARMACEUTICALS and 4.2% of portfolio in LILLY ELI & CO.

The fund managers got completely rid off EXACT SCIENCES CORP (EXAS), CARDINAL HEALTH INC (CAH) and ABBOTT LABS (ABT) stocks. They significantly reduced their stock positions in CYTOKINETICS INC (CYTK), CENTENE CORP DEL (CNC) and VIKING THERAPEUTICS INC (VKTX). Rhenman & Partners Asset Management AB opened new stock positions in AMGEN INC (AMGN), PENNANT GROUP INC (PNTG) and ARROWHEAD PHARMACEUTICALS IN (ARWR). The fund showed a lot of confidence in some stocks as they added substantially to IMMUNOCORE HLDGS PLC (IMCR), LIVANOVA PLC (LIVN) and BRIGHTSPRING HEALTH SVCS INC.

Rhenman & Partners Asset Management AB Annual Return Estimates Vs S&P 500

Our best estimate is that Rhenman & Partners Asset Management AB made a return of 10.83% in the last quarter. In trailing 12 months, it's portfolio return was 14.42%.

Performance
S&P 500

New Buys

Ticker	$ Bought
amgen inc	11,783,200
pennant group inc	10,059,300
arrowhead pharmaceuticals in	9,593,360
ideaya biosciences inc	8,642,500
bridgebio pharma inc	6,241,580
charles riv labs intl inc	4,388,560
oscar health inc	3,736,200
ascendis pharma a/s	3,198,600

New stocks bought by Rhenman & Partners Asset Management AB

Additions

Ticker	% Inc.
immunocore hldgs plc	442
livanova plc	258
brightspring health svcs inc	230
vera therapeutics inc	223
nuvalent inc	211
stevanato group s p a	188
doximity inc	174
janux therapeutics inc	125

Additions to existing portfolio by Rhenman & Partners Asset Management AB

Reductions

Ticker	% Reduced
cytokinetics inc	-82.62
centene corp del	-72.81
viking therapeutics inc	-61.63
ionis pharmaceuticals inc	-48.87
dianthus therapeutics inc	-43.2
biontech se	-41.82
inspire med sys inc	-41.31
privia health group inc	-35.63

Rhenman & Partners Asset Management AB reduced stake in above stock

Sold off

Ticker	$ Sold
annexon inc	-2,510,150
dynavax technologies corp	-7,665,960
exact sciences corp	-19,039,100
akero therapeutics inc	-10,948,900
ultragenyx pharmaceutical inc	-3,591,550
abbott labs	-13,193,100
cardinal health inc	-14,754,200
merus n v	-5,037,020

Rhenman & Partners Asset Management AB got rid off the above stocks

Sector Distribution

Rhenman & Partners Asset Management AB has about 93.6% of it's holdings in Healthcare sector.

Sector	%
Healthcare	93.6
Others	6.4

Market Cap. Distribution

Rhenman & Partners Asset Management AB has about 63.7% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
LARGE-CAP	55.4
MID-CAP	22.4
SMALL-CAP	9.1
MEGA-CAP	8.3
UNALLOCATED	4.4

Stocks belong to which Index?

About 76% of the stocks held by Rhenman & Partners Asset Management AB either belong to S&P 500 or RUSSELL 2000 index.

Index	%
S&P 500	45.5
RUSSELL 2000	30.5
Others	24

Top 5 Winners (%)		%
	structure therapeutics inc	135.0 %
NRIX	nurix therapeutics inc	73.1 %
RLAY	relay therapeutics inc	62.1 %
MLTX	moonlake immunotherapeutics	55.7 %
GH	guardant health inc	46.1 %

Top 5 Winners ($)		$
LLY	lilly eli & co	14.9 M
REGN	regeneron pharmaceuticals	10.2 M
AXSM	axsome therapeutics inc	8.8 M
GKOS	glaukos corp	6.9 M
	structure therapeutics inc	6.8 M

Top 5 Losers (%)		%
JANX	janux therapeutics inc	-35.8 %
DOCS	doximity inc	-30.8 %
ACLX	arcellx inc	-16.2 %
STVN	stevanato group s p a	-15.9 %
TGTX	tg therapeutics inc	-15.6 %

Top 5 Losers ($)		$
DOCS	doximity inc	-7.3 M
EHC	encompass health corp	-2.8 M
ALNY	alnylam pharmaceuticals inc	-2.3 M
PRCT	procept biorobotics corp	-2.1 M
JANX	janux therapeutics inc	-1.7 M

Rhenman & Partners Asset Management AB Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB has 94 stocks in it's portfolio. About 29.4% of the portfolio is in top 10 stocks. DOCS proved to be the most loss making stock for the portfolio. LLY was the most profitable stock for Rhenman & Partners Asset Management AB last quarter.

Last Reported on: 13 Feb, 2026

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
A	agilent technologies inc	0.25	20,000	2,721,400	new

ABBV	abbvie inc	2.36	110,575	25,265,300	reduced	-15.19

ABC	cencora inc	2.00	63,375	21,404,900	added	1.6

ABT	abbott labs	0.00	0.00	0.00	sold off	-100

ACLX	arcellx inc	0.81	133,500	8,704,200	added	104

ADPT	adaptive biotechnologies cor	0.92	605,000	9,825,200	added	22.22

AKRO	akero therapeutics inc	0.00	0.00	0.00	sold off	-100

ALGN	align technology inc	1.45	99,000	15,458,800	added	19.28

ALHC	alignment healthcare inc	1.86	1,009,450	19,936,600	reduced	-31.76

ALKS	alkermes plc	0.35	133,250	3,728,340	added	41.76

ALNY	alnylam pharmaceuticals inc	1.70	45,675	18,162,700	added	43.29

AMGN	amgen inc	1.10	36,000	11,783,200	new

ANNX	annexon inc	0.00	0.00	0.00	sold off	-100

ANTX	elevance health inc	0.49	15,000	5,258,250	reduced	-33.33

APLS	apellis pharmaceuticals inc	0.88	374,450	9,406,180	added	61.23

ARWR	arrowhead pharmaceuticals in	0.90	144,500	9,593,360	new

ASND	ascendis pharma a/s	0.30	15,000	3,198,600	new

ATEC	alphatec hldgs inc	0.04	20,000	420,800	added	11.11

AXSM	axsome therapeutics inc	1.96	114,800	20,967,100	reduced	-33.56

BBIO	bridgebio pharma inc	0.58	81,600	6,241,580	new